| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 196,028 | 203,070 | 202,970 | 195,251 |
| Cost of revenue, exclusive of depreciation and amortization presented separately below | 13,419 | 13,350 | 13,364 | 11,684 |
| Product development and technology | 31,012 | 29,933 | 31,142 | 30,139 |
| Sales and marketing | 83,532 | 84,870 | 84,542 | 89,867 |
| General and administrative | 32,014 | 28,379 | 29,630 | 25,619 |
| Depreciation and amortization | 21,431 | 19,729 | 20,912 | 17,535 |
| Total costs and operating expenses | 181,408 | 176,261 | 179,590 | 174,844 |
| Operating income | 14,620 | 26,809 | 23,380 | 20,407 |
| Other (expense) income | 0 | 694 | - | -2,660 |
| Loss on extinguishment of debt | 0 | - | - | -2,077 |
| Interest income | 2,309 | 2,803 | 3,932 | 4,797 |
| Interest expense | 10,829 | 10,729 | 10,644 | 12,355 |
| Total other expense, net | -8,520 | -7,232 | -6,712 | -12,295 |
| Income before income taxes | 6,100 | 19,577 | 16,668 | 8,112 |
| Income tax expense | 4,981 | 6,734 | 5,616 | 4,147 |
| Net income | 1,119 | 12,843 | 11,052 | 3,965 |
| Basic (in shares) | 346,776,000 | 356,623,000 | 379,196,000 | 379,667,000 |
| Basic (in usd per share) | 0 | 0.04 | 0.03 | 0.01 |
| Diluted (in shares) | 347,810,000 | 357,159,000 | 379,656,000 | 388,504,000 |
| Diluted (in usd per share) | 0 | 0.04 | 0.03 | 0.01 |
GoodRx Holdings, Inc. (GDRX)
GoodRx Holdings, Inc. (GDRX)